Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
Operating activities
Net loss	$ (12,718)	$ (19,357)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense on liability related to the sales of future royalties, net of issuance costs accretion	5,435	4,743	$ 9,779
Depreciation	169	72
Share-based compensation expense	1,415	2,182
Change in fair value of warrant liabilities	(1,927)	(1,206)
Issuance costs allocated to warrant liabilities	0	787
Amortization and accretion of available-for-sale investments, net	0	(109)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,155)	795
Other assets and liabilities	(25)	(497)
Accounts payable and accrued liabilities (includes $254 to a related party for the six months ended June 30, 2024)	(1,753)	(1,091)
Deferred revenue	0	150
Net cash used in operating activities	(10,559)	(13,531)
Investing activities
Acquisition of property and equipment	(9)	(480)
Purchase of short-term investments	0	(11,014)
Net cash used in investing activities	(9)	(11,494)
Financing activities
Proceeds from issuance of common stock and warrants under registered direct offering, net of issuance costs	0	13,860
Proceeds from at-the-market sales agreement, net of issuance costs	1,411	450
Payments	(1,500)	0
Proceeds from exercise of stock options	0	12
Proceeds from shares issued under employee stock purchase plan	13	21
Net cash (used in) provided by financing activities	(76)	14,343
Net decrease in cash and cash equivalents	(10,644)	(10,682)
Cash and cash equivalents, beginning of period	20,020	28,920	28,920
Cash and cash equivalent, end of period	9,376	18,238	$ 20,020
Supplemental disclosure
Purchase of property and equipment included in accrued liabilities	$ 0	$ 4